<DOC>
	<DOCNO>NCT02930967</DOCNO>
	<brief_summary>A Chimeric Switch Receptor , construct fuse PD1 extracellular ligand bind domain CD28 intracellular costimulatory domain , design target PD-L 1 positive tumor . In single-arm , open-label , one center , dose escalation clinical study , main purpose determine safety efficacy infusion autologous Chimeric Switch Receptor modify T cell ( CSR T ) adult patient PD-L1 positive , recurrent metastatic malignant tumor .</brief_summary>
	<brief_title>Chimeric Switch Receptor Modified T Cells Patients With PD-L1+ Recurrent Metastatic Malignant Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Patients PDL1 positive , recurrent metastatic malignant tumor , include limited pancreatic cancer , renal cancer , colorectal cancer , lymphoma , breast cancer lung cancer ; 2. measurable tumor RECIST1.1 standard ; 3. patient 18 70 year old ; 4. life expectancy &gt; 3months ; 5 . KPS ≥70 ; 6. satisfactory major organ function : adequate heart function LVEF≥50 % ; obvious abnormities ECG ; pulse oximetry ≥ 90 % ; cockcroftgault creatinine clearance≥40 ml/min ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3ULN ; Bilirubin ≤2.0 mg/dl ; 7 . Blood : Hgb ≥ 80 g/L , ANC ≥ 1×10^9/L , PLT ≥ 50×10^9/L ; 8. woman reproductive potential must negative pregnancy test . Male female reproductive potential must agree use birth control study one year post study . 1. patient prior history autoimmune disease disease need longterm use systemic hormone drug immunosuppressive therapy 2. active infection . 3 . HIV positive . 4. active hepatitis B virus infection hepatitis C virus infection . 5. currently enrol study . 6. patient , opinion investigator , may eligible able comply study . 7. patient allergic disease , allergic T cell product biological agent use study . 8. patient whose tumor metastasize bone , clinical sign bone metastasis , bone joint pain . 9. patient brain metastasis , clinical sign brain metastasis , loss selfconsciousness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>